alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 7,326–7,350 of 10,985 studies · free to read (page 294 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of neurochemistry 2008-07-01

Recent findings suggest that hypercholesterolemia may contribute to the onset of Alzheimer's disease-like dementia but the underlying mechanisms remain unknown. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Progress in neurobiology 2006-12-06

Microglia constitute the primary resident immune surveillance cell in the brain and are thought to play a significant role in the pathogenesis of several neurodegenerative disorders, such as Alzheimer's disease, multiple sclerosis, Parkinson's disease and HIV-associated dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Inflammation and neurodegenerative diseases

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The American journal of clinical nutrition 2006-02-01

The decline in mental fitness associated with Alzheimer disease is accompanied by physical changes in the brain, including the development of characteristic plaques and neurofibrillary tangles, but the pathogenesis of those changes is not clear. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of virology 2001-11-01

The viral determinants that underlie human immunodeficiency virus type 1 (HIV-1) neurotropism are unknown, due in part to limited studies on viruses isolated from brain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Neurobiology of aging 2003-03-01

We examined the associations of postmortem neocortical immunoreactivities for microglia, astrocytes, Abeta and Tau with cognitive changes in clinically characterized subjects with pathological diagnoses (CERAD classification) of definite AD (9), possible AD (15) and age-matched controls (11). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

White matter damage is associated with matrix metalloproteinases in vascular dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Stroke 2001-05-01

Vascular disease causes multi-infarct dementia (MID) or Binswanger's disease (BD), the latter of which is a progressive form of vascular dementia (VaD) associated pathologically with fibrinoid and hyaline changes in brain arterioles with injury to the white matter. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Oxidized cholesterol as the driving force behind the development of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in aging neuroscience 2015-06-19

Alzheimer's disease (AD), the most common neurodegenerative disorder associated with dementia, is typified by the pathological accumulation of amyloid Aβ peptides and neurofibrillary tangles (NFT) within the brain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Geospatial analysis of patients’ social determinants of health for health systems science and disparity research

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International Anesthesiology Clinics 2022-12-08

The cross-disciplinary expertise, required for GA, common in the days before medical specialization and enabled by the relative paucity of development in various fields compared with today, can be reborn with the advent of Electronic Health Records (EHR) systems that make the tools of medical geography accessible to a wide variety of health care researchers and clinical subspecialties. 4 key findings →

Participants: 127 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2023-07-01

Approximately half of Medicare beneficiaries are enrolled in Medicare Advantage (MA), a private plan alternative to traditional Medicare (TM). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Variations in Medicare Advantage Switching Rates Among African American and Hispanic Medicare Beneficiaries With Alzheimer’s Disease and Related Dementias, by Sex and Dual Eligibility

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journals of Gerontology Series B 2022-09-08

The study included 2,284,175 FFS Medicare beneficiaries with an ADRD diagnosis in 2017. 5 key findings →

Participants: 2,284,175 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tea, talk and technology: patient and public involvement to improve connected health ‘wearables’ research in dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Research Involvement and Engagement 2017-08-01

Discussions revealed that people were generally supportive of this type of research, provided they gave informed consent and that devices were discreet, comfortable and easy to use. 4 key findings →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluating The Accuracy Of Medicare Risk Adjustment For Alzheimer’s Disease And Related Dementias

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Health Affairs 2022-09-01

In 2020 Medicare reintroduced Alzheimer's disease and related dementias (ADRD) Hierarchical Condition Categories (HCCs) to risk-adjust Medicare Advantage and accountable care organization (ACO) payments. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journal of Rheumatology 2018-02-15

Of 15,390 narratives collected from 3139 patients with PsA for exploratory analysis, physical concepts were the most common (81.5%), followed by emotional (50.7%), cognitive (20.0%), role activity (8.1%), and social (5.6%) concepts. 5 key findings →

Participants: 3,139 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Chronic Kidney Disease Is a Potential Risk Factor for the Development of Purple Urine Bag Syndrome

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the American Geriatrics Society 2009-10-01

As they mix together, they become purple.2 According to a few previous reports, PUBS often occurred in elderly women who are bedridden, chronically catheterized, and constipated.3 In addition, PUBS was found in alkaline urine and with higher bacterial counts.3,4 Because of lack of significant patient numbers, the clinical background, underlining diseases, urinanalysis, and incidence of PUBS have not been well documented. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed